Johnson & Johnson HIV combination succeeds in mid-stage study

(Reuters) – A cocktail of Johnson & Johnson’s HIV compound and an experimental drug from ViiV Healthcare met the main goal of a mid-stage study, becoming the second combination to do so. J&J’s pharmaceuticals business chairman, Paul Stoffels, said the company hopes to have the combination on the market by 2020. The combination of J&J’s rilpivirine and ViiV’s cabotegravir showed that it was as good as three pills a day at maintaining minimal viral levels in HIV-infected patients when given together every four or eight weeks.
Sexual Health News Headlines – Yahoo! News